Thus, we infer that using Kv1.3-specific blockers as attractive therapeutic agents to mitigate Aβ-induced pro-inflammatory microglia, which are highly relevant to AD pathogenesis. The gene discussed is KCNA3; the disease is Alzheimer disease.